Last reviewed · How we verify
Abraxane combined with liposomal doxorubicin — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Abraxane combined with liposomal doxorubicin (Abraxane combined with liposomal doxorubicin) — Sun Yat-sen University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Abraxane combined with liposomal doxorubicin TARGET | Abraxane combined with liposomal doxorubicin | Sun Yat-sen University | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Abraxane combined with liposomal doxorubicin CI watch — RSS
- Abraxane combined with liposomal doxorubicin CI watch — Atom
- Abraxane combined with liposomal doxorubicin CI watch — JSON
- Abraxane combined with liposomal doxorubicin alone — RSS
Cite this brief
Drug Landscape (2026). Abraxane combined with liposomal doxorubicin — Competitive Intelligence Brief. https://druglandscape.com/ci/abraxane-combined-with-liposomal-doxorubicin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab